# Dinger PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dinger

> Dinger, sponsored by Schrodinger, Inc. (SDGR): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | dinger |
| Codes | SGR-3515 |
| Sponsor | Schrodinger, Inc. (SDGR) https://sec-api.dev/companies/sdgr/catalysts |
| Indications | [advanced solid tumors](https://sec-api.dev/indications/advanced-solid-tumors) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: advanced solid tumors.
- First seen 2025-05-07, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001490978-26-000076): "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." https://www.sec.gov/Archives/edgar/data/1490978/000149097826000076/sdgr-20260930.htm
- SEC Form 10-Q (accession 0001490978-26-000068): "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." https://www.sec.gov/Archives/edgar/data/1490978/000149097826000068/sdgr-20260630.htm
- SEC Form 10-Q (accession 0001490978-26-000037): "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." https://www.sec.gov/Archives/edgar/data/1490978/000149097826000037/sdgr-20260331.htm
- SEC Form 10-K (accession 0001490978-26-000010): "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." https://www.sec.gov/Archives/edgar/data/1490978/000149097826000010/sdgr-20251231.htm
- SEC Form 10-Q (accession 0001490978-25-000117): "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000117/sdgr-20250930.htm
- SEC Form 10-Q (accession 0001490978-25-000100): "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000100/sdgr-20250630.htm
- SEC Form 10-Q (accession 0001490978-25-000059): "In July 2024, we initiated dosing in a Phase 1 clinical trial of SGR-3515 in patients with advanced solid tumors." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000059/sdgr-20250331.htm

### Q4 2025: interim data readout

- Status: delayed. Date confidence: quarter. Stage: 2.
- First seen 2024-11-12, last confirmed 2025-08-06.
- Press release filed with the SEC (EX-99) (accession 0001490978-25-000099): "Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025" https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001490978-25-000099): "Initial clinical data from this study are expected in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000099/sdgr-20250630xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001490978-25-000058): "Initial clinical data from this study are expected in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000058/sdgr-20250331xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001490978-25-000013): "Initial clinical data from this study is expected in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000013/sdgr-20241231xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001490978-24-000088): "Initial clinical data from this study is expected in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1490978/000149097824000088/sdgr-20240930xexx991xscena.htm
- SEC Form 10-Q (accession 0001490978-25-000100): "We anticipate reporting initial data from the trial in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000100/sdgr-20250630.htm
- SEC Form 10-Q (accession 0001490978-25-000059): "We anticipate reporting initial data from the trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000059/sdgr-20250331.htm
- SEC Form 10-K (accession 0001490978-25-000014): "We anticipate reporting initial data from the trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000014/sdgr-20241231.htm
- SEC Form 10-Q (accession 0001490978-24-000089): "The trial is a dose-escalation trial designed to evaluate the safety, pharmacokinetics, pharmacodynamics, preliminary anti-tumor activity and recommended Phase 2 dose of SGR-3515, and we anticipate reporting initial data from the trial in the second half of 2025." https://www.sec.gov/Archives/edgar/data/1490978/000149097824000089/sdgr-20240930.htm

### Q2 2026: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-11-05, last confirmed 2026-02-25.
- Press release filed with the SEC (EX-99) (accession 0001490978-25-000116): "Initial clinical data are now expected in the first half of 2026 as the company works toward completing dose escalation." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000116/sdgr-20250930xexx991.htm
- SEC Form 10-K (accession 0001490978-26-000010): "We anticipate reporting initial data from the trial in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1490978/000149097826000010/sdgr-20251231.htm
- SEC Form 10-Q (accession 0001490978-25-000117): "We anticipate reporting initial data from the trial in the first half of 2026." https://www.sec.gov/Archives/edgar/data/1490978/000149097825000117/sdgr-20250930.htm

## Same indication

- [ARV-6723](https://sec-api.dev/pdufa/arv-6723) (ARVN)
- [BNT324](https://sec-api.dev/pdufa/bnt324) (BNTX)
- [CLN-617](https://sec-api.dev/pdufa/cln-617) (CGEM)
- [FT825](https://sec-api.dev/pdufa/ft825) (FATE)
- [IM-1340](https://sec-api.dev/pdufa/im-1340) (IMNM)
- [IM-1617](https://sec-api.dev/pdufa/im-1617) (IMNM)
- [PSV359](https://sec-api.dev/pdufa/psv359) (CATX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dinger.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dinger PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dinger

```bibtex
@misc{secapidev_pdufa_dinger_20261116,
  title        = {Dinger PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dinger}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dinger_20261116","title":"Dinger PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dinger","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
